{"id":7972,"date":"2016-07-18T00:00:00","date_gmt":"2016-07-17T22:00:00","guid":{"rendered":"https:\/\/idibell.cat\/blog\/2016\/07\/18\/tractivus-finalista-del-premi-forum-dinversio-daccio\/"},"modified":"2020-08-07T10:41:12","modified_gmt":"2020-08-07T08:41:12","slug":"tractivus-finalista-del-premi-forum-dinversio-daccio","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2016\/07\/tractivus-finalista-del-premi-forum-dinversio-daccio\/","title":{"rendered":"Tractivus, finalista del Premi F\u00f2rum d\u2019Inversi\u00f3 d\u2019ACCI\u00d3"},"content":{"rendered":"<p>El passat 14 de juliol, l\u2019\u00e0rea d\u2019innovaci\u00f3 i desenvolupament de negoci de l\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) va participar en una nova edici\u00f3 del <strong>F\u00f2rum d\u2019Inversi\u00f3 <\/strong><strong>d&#8217;ACCI\u00d3 <\/strong>(Generalitat de Catalunya) a trav\u00e9s de la<strong> presentaci\u00f3 del projecte de Tractivus<\/strong>, una spin-off IDIBELL-IQS. Aquesta jornada, que enguany arriba a la seva <strong>21a edici\u00f3<\/strong>, constitueix un dels principal <strong>punts de trobada entre emprenedors i inversors<\/strong> a Catalunya.<\/p>\n<p><strong>Tractivus <\/strong>va ser una de les 21 empreses escollides<\/p>\n<p>per participar en la competici\u00f3 pel <strong>Premi F\u00f2rum d\u2019Inversi\u00f3<\/strong><strong>, <\/strong>que es lliura al projecte amb m\u00e9s potencial d\u2019innovaci\u00f3. Joan Gilabert, CEO de Tractivus, va presentar en un <em>elevator pitch<\/em> d\u2019un minut el projecte de <strong>disseny de dispositius m\u00e8dics personalitzats i antibacterians amb impressi\u00f3 3D <\/strong>davant l\u2019atenta mirada del p\u00fablic assistent, que amb les seves votacions el va escollir com a 3r finalista dins l\u2019\u00e0mbit de ci\u00e8ncies de la salut. Finalment, l\u2019empresa catalana Nektria va ser la guanyadora del certamen.<\/p>\n<p>Paral\u00b7lelament, el F\u00f2rum va ser tamb\u00e9 l\u2019espai per a <strong>400 reunions de networking<\/strong> <strong>entre emprenedors, inversors privats i representants<\/strong> de fons de capital risc; l\u2019IDIBELL hi va participar activament introduint els projectes que composen el seu portafoli de propostes d\u2019innovaci\u00f3 i transfer\u00e8ncia tecnol\u00f2gica per tal de cercar finan\u00e7ament en base al seu potencial de negoci. A m\u00e9s, l&#8217;edici\u00f3 d&#8217;enguany del f\u00f2rum va comptar amb la pres\u00e8ncia destacada d&#8217;<strong>Alon<\/strong> <strong>Lifshitz<\/strong>, <em>Managing director<\/em> de Blumberg Capital, que es va encarregar de la confer\u00e8ncia inaugural, i amb <strong>empreses i inversors d&#8217;Israel<\/strong>, pa\u00eds convidat d&#8217;aquesta edici\u00f3.<\/p>\n<p>El F\u00f2rum d\u2019Inversi\u00f3 d\u2019ACCI\u00d3<\/p>\n<p>tamb\u00e9 va servir per presentar el <a href=\"http:\/\/accio.gencat.cat\/cataleg-empreses-forum\"><strong>Cat\u00e0leg d\u2019Empreses del 2016<\/strong><\/a>, que recull els <strong>50 millors projectes empresarials<\/strong> d\u2019entre les m\u00e9s de 100 propostes rebudes.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>F\u00f2rum d\u2019Inversi\u00f3 d&#8217;ACCI\u00d3 presentaci\u00f3 del projecte de Tractivus 21a edici\u00f3 punts de trobada entre emprenedors i inversors Tractivus Premi F\u00f2rum d\u2019Inversi\u00f3 , disseny de dispositius m\u00e8dics personalitzats i antibacterians amb impressi\u00f3 3D 400 reunions de networking entre emprenedors, inversors privats i representants Alon Lifshitz empreses i inversors d&#8217;Israel Cat\u00e0leg d\u2019Empreses del 2016 50 millors projectes empresarials<\/p>\n","protected":false},"author":6,"featured_media":10775,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1,448,493],"tags":[],"class_list":["post-7972","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar","category-apoptosi-i-cancer","category-innovacio"],"publishpress_future_action":{"enabled":false,"date":"2024-12-30 00:24:46","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7972"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7972\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10775"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}